Flexible capital to help growing business scale
TPG’s Growth platform provides us with the ability to invest in companies that are earlier in their lifecycle, are smaller in size, or have profiles that are different from what we’d consider for our Capital platform. Our family of growth funds has developed organically as new areas of opportunity emerge, particularly in technology and media.
Invested Since Inception
Growth equity is one of the fastest growing private equity strategies in the market today. TPG was early to recognize this opportunity, launching TPG Growth in 2007 to meet the unique needs of earlier-stage companies, from traditional minority growth investing to growth buyouts and specialty capital. TPG’s West Coast roots, value-added operating approach, global reach, and sector depth give us a distinct advantage in growth investing and position us as a valued partner for entrepreneurs.
TPG Digital Media
Established in 2017, TPG Digital Media (TDM) is a flexible source of capital created specifically to pursue investment opportunities in digital media. TDM leverages TPG’s long history of studying and pursuing themes around the creation and distribution of content to build market-leading businesses in attractive verticals within the digital media landscape.
TPG Technology Adjacencies
TPG Technology Adjacencies (TTAD) developed organically out of our technology investing practice in 2018. We saw significant value being created in the private markets as tech companies increasingly opted to stay private through more advanced stages of growth. This is a new era in the technology market that requires flexible capital with a full-suite, full-cycle approach to investing, and we created TTAD specifically for this opportunity.
deployed across two funds
TPG Life Sciences Innovation
As the pace of research, development, and innovation in the life sciences sector accelerates, TPG is uniquely positioned to be a capital provider of choice to emerging leaders. TPG Life Sciences Innovation (LSI) is a new strategy that will invest in companies that are developing new therapeutic modalities, biologics, and small molecules, as well as later-stage opportunities in digital health, medical devices, diagnostics, and innovation services.
in historical TPG life sciences investments
Our other platforms
TPG puts capital to work through platforms that are made up of 17 distinctive products—all of which were created by growing organically into opportunities we identified through deep work in key sectors and geographies.
Large-scale control-oriented private equity investing
Private equity investing focused on both societal and financial outcomes
Generating income through investments in private equity, public equity and debt
Differentiated strategies built to address specific market opportunities